(Q37779321)

23 August 2017

1 reference

title

Advances in chemotherapy in advanced non-small-cell lung cancer (English)

1 reference

23 August 2017

1 reference

1 reference

Antonio Rossi

2

0 references

Cesare Gridelli

6

object named as

Cesare Gridelli

1 reference

23 August 2017

Paolo Maione

1

1 reference

23 August 2017

Paola Claudia Sacco

3

1 reference

23 August 2017

Maria Anna Bareschino

4

1 reference

23 August 2017

Clorinda Schettino

5

1 reference

23 August 2017

language of work or name

English

0 references

publication date

12 August 2010

1 reference

Expert Opinion on Pharmacotherapy

23 August 2017

1 reference

23 August 2017

11

1 reference

23 August 2017

2997-3007

1 reference

23 August 2017

18

1 reference

Global cancer statistics, 2002

23 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511615

EUROCARE-3: survival of cancer patients diagnosed 1990-94--results and commentary.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511615

Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511615

Recent issues in first-line treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511615

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511615

Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511615

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511615

Screening for epidermal growth factor receptor mutations in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511615

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511615

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511615

Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511615

Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511615

The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511615

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511615

Sequential, alternating, and maintenance/consolidation chemotherapy in advanced non-small cell lung cancer: a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511615

Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511615

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511615

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511615

Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.511615

Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer.

21 January 2018

1 reference

30 December 2023

https://opencitations.net/index/api/v1/citations/10.1200/JCO.2008.19.9331

Identifiers

DOI

10.1517/14656566.2010.511615

1 reference

23 August 2017

1 reference